Mepenex (Meropenem Anhydrous)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, preventing the cross‑linking of peptidoglycan strands. This disruption leads to cell‑wall weakening, osmotic lysis, and rapid bactericidal activity against a broad range of Gram‑positive, Gram‑negative, and anaerobic organisms.

The dosage of Mepenex is determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and local antimicrobial guidelines. No fixed regimen is provided here; the prescriber sets the appropriate dose and infusion rate.

Safety data for meropenem in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Mepenex, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Meropenem belongs to the carbapenem class, offering broader spectrum coverage and greater stability against β‑lactamases than most penicillins and cephalosporins. Compared with other carbapenems such as imipenem or ertapenem, meropenem provides enhanced activity against Pseudomonas aeruginosa and Acinetobacter species, making it a preferred option for multidrug‑resistant infections.

Mepenex should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Once reconstituted, it should be used promptly according to the manufacturer’s stability guidelines and kept in a controlled‑temperature environment during administration.

Mepenex is supplied as an injectable solution for intravenous infusion. It is administered by a healthcare professional through a peripheral or central venous line, typically over a 15‑ to 30‑minute infusion period, with the exact rate determined by the prescribing clinician.

Serious adverse events include seizures (particularly in patients with renal impairment or CNS disorders), severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, neutropenia, thrombocytopenia, and acute kidney injury. Prompt medical attention is required if any of these occur.

Mepenex is contraindicated in patients with a documented hypersensitivity to meropenem, other carbapenems, or any component of the formulation. Caution is also advised for individuals with a history of seizures, severe renal impairment, or known colonisation with carbapenem‑resistant organisms.